Friday, July 30, 2021 11:06:40 AM
Scripts for week ending July 23, 2021
Overall drug TRx are -0.5% w/w
Vascepa
TRx 85,070; -0.3% (-234) w/w; -2.3% y/y
NRx 37,910; -0.3% (-108) w/w; -5.7% y/y
Ref 47,160; -0.3% (-126) w/w; +0.6% y/y
Lovaza (Generic & Brand)
TRx 63,219; -0.4% (-247) w/w; +4.9% y/y
NRx 30,998; -0.8% (-240) w/w; +4.0% y/y
Ref 32,221; -0.0% (-7) w/w; +5.9% y/y
Generic Vascepa
TRx 15,623; +8.8% (+1,267) w/w; As % of total V: 15.5%
NRx 9,038; +11.3% (+916) w/w; As % of total V: 19.3%
Ref 6,585; +5.6% (+351) w/w; As % of total V: 12.3%
Generic Vascepa by Manufacturer
Hikma TRx 12,075; Generic share 77.3%; Total V share 12.0%
Reddy TRx 3,548; Generic share 22.7%; Total V share 3.5%
Overall drug TRx are -0.5% w/w
Vascepa
TRx 85,070; -0.3% (-234) w/w; -2.3% y/y
NRx 37,910; -0.3% (-108) w/w; -5.7% y/y
Ref 47,160; -0.3% (-126) w/w; +0.6% y/y
Lovaza (Generic & Brand)
TRx 63,219; -0.4% (-247) w/w; +4.9% y/y
NRx 30,998; -0.8% (-240) w/w; +4.0% y/y
Ref 32,221; -0.0% (-7) w/w; +5.9% y/y
Generic Vascepa
TRx 15,623; +8.8% (+1,267) w/w; As % of total V: 15.5%
NRx 9,038; +11.3% (+916) w/w; As % of total V: 19.3%
Ref 6,585; +5.6% (+351) w/w; As % of total V: 12.3%
Generic Vascepa by Manufacturer
Hikma TRx 12,075; Generic share 77.3%; Total V share 12.0%
Reddy TRx 3,548; Generic share 22.7%; Total V share 3.5%
Recent AMRN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
